There are also other PARP inhibitors currently undergoing global clinical trials or in development for the treatment of BC, such as niraparib, rucaparib, and veliparib, and they could show good results administered with platinum-based chemotherapy for HER2-negative, gBRCA-mutated locally advanced or/and metastatic BC [57,58]. This evidence concerns the gene PARP1 and breast cancer.